Summit Therapeutics Inc. - Common Stock (SMMT)

Positive expectations from key clinical trials, delisting fears and some regulatory changes triggered a flurry of discussions on Stocktwits for these tickers for the week ended April 11, 2025.

Last week's top performers: SMMT, HMY, AU, CVNA, HOOD, NEM, AVGO, GFI, KGC, CEG. Are they in your portfolio? #stockmarket #investing

Summit Therapeutics' ivonescimab shows strong efficacy in trials, with Cantor Fitzgerald predicting a 50% market share in the $100B VEGF x PD-(L)1 space.

Top 10 large-cap stocks rose last week: Rubrik 23.17%, Applovin 17.21%, Summit Therapeutics 16.93%, Intel 16.52%, VG 16.03%, GE Vernova 14.01%, Samsara 11.96%, Antero Resources 11.68%, Super Micro 10.28%, ConocoPhillips 9.18%

Message volume on Stocktwits jumped 2,500%, with retail traders focusing on Summit’s partnership to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates for solid tumors.

The major indices struggled to maintain early momentum on Monday, but appear to climbing back with the S&P 500 and Dow Jones both green in midday trading. 

All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.